Glioblastoma
The most common length of survival following diagnosis is 12 to 15 months, with fewer than 3% to 5% of people surviving longer than five years. Without treatment survival is typically 3 months.
IDH1
Mutations in "IDH1" are also implicated in cancer. Originally, mutations in "IDH1" were detected in an integrated genomic analysis of human glioblastoma multiforme. Since then it has become clear that mutations in "IDH1" and its homologue "IDH2" are among the most frequent mutations in diffuse gliomas, including diffuse astrocytoma, anaplastic astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, anaplastic oligoastrocytoma, and secondary glioblastoma. Mutations in "IDH1" are often the first hit in the development of diffuse gliomas, suggesting "IDH1" mutations as key events in the formation of these brain tumors. Glioblastomas with a wild-type "IDH1" gene have a median overall survival of only 1 year, whereas "IDH1"-mutated glioblastoma patients have a median overall survival of over 2 years.